KRSNAA DIAGNOSTICS share price has zoomed 5% and is presently trading at Rs 935.8.
Meanwhile, the BSE HEALTHCARE index is at 43,154.1 (down 0.1%).
Among the top gainers in the BSE HEALTHCARE index today are POLY MEDICURE (up 8.1%) and GSK Pharma (up 3.7%).
Cipla (down 3.9%) and Jubilant Pharmova (down 3.6%) are among the top losers today.
Over the last one year, KRSNAA DIAGNOSTICS has moved up from Rs 700.3 to Rs 935.8, registering a gain of Rs 235.5 (up 33.6%).
On the other hand, the BSE HEALTHCARE index has moved up from 27,385.2 to 43,154.1, registering a gain of 57.6% during the last 12 months.
The top gainers among the BSE HEALTHCARE index stocks during this same period were Jubilant Pharmova (up 179.9%), SUVEN PHARMACEUTICALS (up 125.9%) and Glenmark Pharma (up 125.2%).
Dear Reader: If You Invest in Midcap Stocks, this is for You
The BSE Sensex is at 80,243.9 (down 0.2%).
The top losers among the BSE Sensex today are ICICI Bank (down 1.7%) and Axis Bank (down 1.1%). The most traded stocks in the BSE Sensex are Power Grid Corp. and Tata Motors.
In the meantime, NSE Nifty is at 24,437.3 (down 0.1%). Cipla and SBI LIFE INSURANCE are among the top losers in NSE NIFTY.
Over the last 12 months, the BSE Sensex has moved up from 64,112.7 to 80,243.9, registering a gain of 16,131.3 points (up 25.2%).
KRSNAA DIAGNOSTICS net profit grew 86.7% YoY to Rs 196 million for the quarter ended September 2024, compared to a profit of Rs 105 million a year ago. Net sales rose 19.9% to Rs 1,863 million during the period as against Rs 1,554 million in July-September 2023.
For the year ended March 2024, KRSNAA DIAGNOSTICS reported 8.5% decrease in net profit to Rs 568 million compared to net profit of Rs 621 million during FY23. Revenue of the company grew 27.2% to Rs 6,196 million during FY24.
The current Price to earnings ratio of KRSNAA DIAGNOSTICS, based on rolling 12 month earnings, stands at 43.7.
Equitymaster requests your view! Post a comment on "KRSNAA DIAGNOSTICS Gains 5%; BSE HEALTHCARE Index Down 0.1%". Click here!
Comments are moderated by Equitymaster, in accordance with the Terms of Use, and may not appear
on this article until they have been reviewed and deemed appropriate for posting.
In the meantime, you may want to share this article with your friends!